First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)
Read time: 2 mins
Last updated:1st May 2012
Primary Sponsor: Novartis Pharmaceuticals
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
|Date last updated at source||2016-04-27|
|Study start date||2012-05-01|
|Estimated primary completion date||2016-12-01|